WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A REVIEWON : GENE THERAPY IN CANCER

Mr. Akshay Sitaram Jadhav, Ms. Pallavi Jadhav, Ms. Pallavi Shivaji Kale

Pratibhatai Pawar College of Pharmacy, Shrirampur

ABSTRACT :

Gene therapy may be a new tool utilized in combating completely different diseases. It began to be Intensely utilized in analysis comes in 1989 and vital advances are created in this medical aid since then. The bulk of factor medical aid clinical trials are targeted on cancer and so it absolutely was no coincidence that the primary industrial factor treatment in 2003 was for a neoplasia. Withal, some unfavorable events are ascertained within the use of this therapy leading to its strict police investigation and within the promotion of making safer therapeutic regimens. Presently there are good form of factor medical aid proposals involving an oversized variety of antineoplastic molecular mechanisms that may conceivably pave the method for extremely effective treatment choices. Despite the numerous advances that have been created in factor medical aid within the fight against cancer, its effectiveness, safety and industrial availability are still restricted. These limitations are expected to step by step overcome.

Keywords: Cancer, Transference method, Adenovirus, Poxvirus, Retrovirus, Targeted Delivery, Targeted Expression, Therapeutic Gene,

INTRODUCTION :

Cancer may be a unwellness characterised by Associate in Nursing accelerated and uncontrolled growth of cells that have the capability to unfold throughout the body and have an effect on organ perform. Once Detected at a late stage, cancer is usually fatal, so augmentative the look for new medication to assist patients. Factor medical care seems to be Associate in Nursing adequate antineoplastic strategy that presently plays a vital role in analysis comes and incorporates a promising future in clinical oncologic observe.

DEFINITION:

Gene therapy is that the treatment or interference of a illness that's distributed through the insertion of ester sequences (DNA or RNA) into the cell. Genes that carry theinformation necessary to make a supermolecule inside the cell ar typically introduced (figure 1) [Cross D.et al., 2006]. The purpose of this transference of genetic material or of genes is to modify a cellular function that had been abolished or become defective, to introduce a brand new operate or to interfere in associate degree existing operate. Different gene therapy strategies are based on a combination of three key Elements: the genetic material to be transferred, the transference method and the type of target Cell.



Figure 1. Gene therapy is based on the idea that genes or foreign sequences can be inserted into cells through "vehicles" or vectors. A vector acts as a carrier vehicle to deliver a therapeutic passenger into the target cell.

GENETIC MATERIAL TO BE TRANSFERRED :

The majority of ester sequences square measure genes, that is, sequences that may manufacture a functional macromolecule inside a cell. The therapeutic sequence should perform a perform that help fight a unwellness. Within the case of unwellness caused by a defective (mutated) sequence the intention is to introduce a standard sequence. If new tissue is to be created a protein sequence is inserted. In the case of cancer, the goal is to eliminate growth cells or limit their growth. The following square measure the foremost common altered functions of cancerous cells: 1) uncontrolled accelerated growth capability, 2) the spreading to and invasion of important organs, 3) Accelerated angiogenesis and 4) system evasion to avoid being eliminated . Anticancer therapeutic genes can have to be compelled to block these talents of malignant cells or produce cytotoxic effects that directly cause malignant death.[Johann DJ ., et al.,2009]

TRANSFERENCE METHOD :

Functional gene sequences area unit placed in vectors that function vehicles for transporting the sequences to the inside of the cell. Vectors sorts may be microorganism or non-viral [Rojas-Martinez A,et al.,2002] . The Nucleotide sequence or therapeutic gene is inserted into the non-viral vector or into the genome of the microorganism vector victimization biological science and genetic manipulation techniques. There area unit varied forms of non-viral vectors: 1) Naked DNA, that is mostly a circular DNA (such as microorganism plasmid) that's injected directly into the tissues, 2) DNA encircled by in cationic lipids that facilitate it submit to the cellular membrane because of the membrane's Liposoluble part, 3) DNA that's condensed in particles (or encircled by them) that can be nanoparticles and 4) oligonucleotides (generally antisense RNA) to inactivate the genes concerned within the malady method. Naked DNA is that the hottest non-viral system used In clinical trials, followed by cationic lipid/DNA complexes. This sort of vector isn't Inserted into the cell with abundant potency so its distribution is restricted and comparatively low levels of therapeutic macromolecule area unit made. Thus it's used for inserting genes that may, With little or no activity, turn out vital responses as is that the case with growth factors in muscle. Once managing cancer, elevated levels of therapeutic macromolecule production area unit generally required, moreover as a good vector distribution in cancerous tissue. Thus the utilization of non-viral vectors is restricted once operating with cancer. Non-viral vectors would be helpful in antineoplastic therapies that do not require large quantities of therapeutic protein or in which the gene does not act directly on the cancer as is the case in immune system stimulation by vaccines or immunotherapy. [EdelsteinML, et al., 2007].

Viral vectors are the most commonly used vectors to fight cancer. In a general sense their order of importance when used against cancer is first adenovirus, followed by poxvirus, Herpes simplex virus, retrovirus and adeno-associated virus. These viral vectors have been used in multiple clinical trials in humans presenting with different diseases. However, a large Variety of other viruses may also be used as vectors. Each vector has different characteristics in relation to its tropism, activity duration, its integration or non-integration into cellular chromosomes and immunogenicity, to mention a few. Therefore it is very important to be aware of the behaviour of the different types of viral vectors.[Edelstein ML, et al., 2007].

ADENOVIRUS :

The most wide used vectors in factor medical care against cancer area unit adenoviruses. They make up a polymer order virus family of a minimum of fifty one completely different serotypes. Sort five is that the most frequently used as a vector . These viruses ordinarily cause diseases of the metabolismtract, primarily the higher tract. The adenovirus vector system has shown real promise in treating cancer and it is not surprising that the first gene therapy product to be licensed to treat cancer uses an adenovirus.[Nemerow GR et al., 2002]

POXVIRUS:

Poxviruses represent a heterogeneous cluster of desoxyribonucleic acid viruses that are utilised to transport a mess of foreign genes. Vaccinia virus is that the prototypic recombinant Poxvirus [Kaufman HL. et al., 2005]. Vaccinia virus has been used as a vaccinum for variola major for over a hundred and fifty years and there's nice expertise in its clinical use. Poxviruses will infect a broad vary of cells, have a order which will accommodate giant desoxyribonucleic acid inserts (multiple genes), replicate entirely within the living substance of the host cell with high potency (with speedy cell-to-cell spread),do not have the likelihood of body integration and elicit sturdy immune responses.These factors create them particularly well-suited as vaccines for the hindrance and treatment of human immunological disorder virus (HIV) and cancer [Wang E,. et al.,2007, Essajee S, . et al., 2004] . Vaccinia virus has been used as(1) A delivery vehicle for anti-cancer genes, (2) a vaccinum carrier for tumor-associatedAntigens and immunoregulatory molecules in cancer therapy, Associate in nursingd (3) an oncolytic agent that by selection replicates in and lyses cancer cells. [Shen Y.,et al., 2005]

HERPES SIMPLEX VIRUS :

Herpes simplex viruses (HSV) belong to the taxon of Alphaherpesvirinae, which cause infections in humans. Herpes viruses encompass a comparatively massive linear DNA order of double-stranded [Post L, et al., 2007]. Kind one virus is that the virus most often used as a vector for factor therapy. Herpes simplex begins its life cycle by binding heparan sulphate, a proteoglycan found on the surface of the many cell sorts. It afterward interacts with one in every of many cellular receptors nearer to the cell surface and fusion with the cytomembrane happens. Once within the cell, the virus travels on the host body structure to the nucleus, wherever its replication begins or wherever its therapeutic organic phenomenon begins if it's a vector.

RETROVIRUS :

Retroviral genetic material is within the kind of ribonucleic acid. Once a animal virus infects a number cell, it Will introduce its ribonucleic acid along side some enzymes (reverse polymerase and integrase) into the cell. This ribonucleic acid molecule from the animal virus should manufacture a deoxyribonucleic acid copy from its ribonucleic acid molecule before it may be integrated into the cell chromosomes. The genetic material of the virus is then inserted into the cell ordination and becomes a part of the genetic material of the host cell. If this host cell later divides, its descendants can all contain the new genes inserted by the virus.[Nair V., 2008]

ADENO ASSOCIATED VIRUSES :

Adeno-associated viruses from the animal virus family square measure tiny viruses with a order of single stranded desoxyribonucleic acid. They will infect dividing and non-dividing cells. Wild sort adeno-Associated viruses will insert genetic material at a selected web site on body nineteen with nearly100% certainty [Shen Y, et al., 2007, Park K, et al., 2008]. As a result of they will integrate into cellular chromosomes they're useful principally in treating diseases that need sequence activity for long periods of your time. However, some changed adeno-associated infectious agent vectors that don't contain any infectious agent genes however solelythe therapeutic sequence, don't integrate into the cellular order. They're in the main used for muscle and eye diseases, though they're getting down to be wont to deliver genes to the brain.

TARGET CELL: TARGETINGGENE THERAPY TO CANCER :

One of the benefits of factor medical care with relation to ancient therapy or radiotherapy is that the capability to by selection eliminate growth cells whereas inflicting the smallest amount possible harm to healthy tissue. Ideally it ought to even be capable of working at the general level to attack each the first growth and pathological process deposits . Molecular characteristics of willcer will function a flag to mark the somatic cell so it can preferentially be attacked by factor medical care vectors (targeting). There are numerous methods for guiding the therapeutic factor to fight cancer [Dachs GU, et al., 1997]

TARGETED DELIVERY :

Delivery of the vector on to the growth website by intratumoral injection is that the simplest manner to direct medical care towards the cancer and thereby for the most part avoids traditional tissues [Dachs GU, et al., 1997].This option isn't helpful in general treatments or once the growth isn't visible, as in metastasis.The transfer of genes is entirely smitten by the interaction between the vector andTarget cell surface [Nemerow GR.,2002].There area unit variations within the potency of every vector for getting inCells. Another easy strategy includes the exploitation of natural microorganism tropisms, like those exhibited by adenoviruses to focus on respiratory organ epithelial tissue cancer or by herpes simplex virus to target the system. However, the interaction that naturally happens between the vector and target cell surface may be changed so as to extend the doorway of the vectors into theCells and/or send their reaction (figure 2).

Several cancerous cells have Associate in Nursing elevated amount of bound sorts of receptors in their membranes. A decent example is that the profusion of human dermal protein receptor kind two (HER2) in some sorts of carcinoma [Mikheeva G, et al., 2007].The proteins of the microorganism vectors responsible of interaction with cell receptors may be changed so that they specifically unite with a receptor that's chiefly found in cancerous cells.Similarly, naked DNA, and even some microorganism vectors, will kind complexes with proteins (likeAntibodies) or biomolecules, that once acting as specific ligands, facilitate their entrance intoa particular sort of somatic cell through a compatible receptor (figure 2). Associate in Nursing example of this is the recent style of Associate in Nursing animal virus that has been changed in its exterior structure therefore that it's capable of selective delivery of a factor to HER2 positive cancer cells [Mikheeva G, et al., 2008]



Figure 2. Strategies to target both viral and nonviral delivery agents to tumor cells. These include redirecting vectors A) using biomolecules to direct naked DNA to target cells; B and C) using tissue or cancer-specific ligands or monoclonal antibodies incorporated onto the surface of DNA complexes or viral vectors to change native tropism (redirecting virus to a cancer-specific receptor); D) genetically modifying the virus to ablate native receptor interactions and incorporating a novel ligand into one of the coat proteins of the virus.

TARGETED EXPRESSION :

In a cistronral manner it are often aforesaid that a gene may be a purposeful DNA unit that carries codified data which can create later macromolecule or ribonucleic acid sequence production potential. The gene contains each "coding" sequences (cDNA) that confirm what it will, and "non-coding" sequences that confirm once it's active (expressed). In human cells, a gene produces associate ribonucleic acid chain within the nucleus (transcription) that later is translated into a macromolecule in the ribosomes. The expression method involves all the mandatory steps for proteins or functional ribonucleic acid sequences to be made from the data contained in an exceedingly cistron. A gene is said to own a high level of expression or is over-expressed once giant quantities of ribonucleic acid or continuing from that gene area unit detected. The promoter may be a non-coding region ofDNAthat regulates once and wherever a gene is active yet because the amount of ribonucleic acid to be produced. In different words, it regulates organic phenomenon. Though different processes is also involved in dominant gene pattern expression, typically it's promoter activity that'sPrincipally liable for its regulation.[Dachs GU, et al., 1997]

THERAPEUTIC GENE:

Even though a factor has an equivalent operate in healthy tissue as in cancerous tissue, its activity will have an effect on every form of tissue otherwise. The therapeutic factor operate itself will, to a certain extent, direct its result towards growth cells. A factor whose product is cyanogenic for cells in proliferation can a lot of intensely have an effect on malignant cells just because their growth is more accelerated than that of healthy cells.

A product that inhibits growing can have a greater result in tissues wherever there's bigger formation of latest vessels, like in tumors. However, there area unit methods during which the therapeutic factor very directs its result in the main towards malignant cells. An outsized range of tumors area unit secondary to infective agent oncogenic activity. Neoplasms that area unit related to oncogenic viruses specific an outsized amount of infective agent proteins that area unit seldom found in healthy cells. These sorts of macromolecule, infective agent or not, are called tumour associated antigens (TAA).

ACTION MECHANISMS OF GENE THERAPY TO FIGHT CANCER-

Various ways is also developed to eliminate cancerous cells by combining therapeutic genes, the kind of vector and therefore the method within which the medical aid is directed towards the cancer. Not not like automotive designers, solely scientist power is that the limit for making the most effective

gene vehicle with the most effective performance.



Figure 3. Schematic diagram of immunotherapy. Pathway A represents adoptive therapy using TCR gene therapy. Pathway B represents vaccination with dendritic cells expressing a tumor-associated antigen. Pathway C represents immunotherapy with modified cancer cells. Pathway D represents vaccination with immunostimulatory genes in vivo.

IMMUNOTHERAPY: The institution of cancer involves not solely the escape of tumour cells from traditional growth management however additionally their throw off immunologic recognition. The most objective of immunotherapy is to manage or eliminate tumors by enhancing the host's immune reaction to tumor antigens. The term "immunogene therapy" will be outlined as genetically manipulating tumor cells or nerve fiber cells so as to stimulate anticancer immunity; the genes will be transferred in place or ex vivo as a part of the preparation of associate antitumor immunogen (figure 3).Immunogene medical care is rising jointly of the promising treatment modalities for malignant tumors [Chang LJ, et al., 2003].

On the opposite hand, adoptive transfer of antigen-specific T lymphocytes is another form of therapy for cancer. During this case the strategy depends on cloned lymphocyte receptor (TCR) genes which will be wont to manufacture T cell populations of desired specificity to recognize cancer antigens and mediate cancer regression in vivo [Morgan RA, et al., 2006, Stauss HJ, et al., 2008]. Thus, specific ways of therapy that are used to reinforce antitumor responses will be classified into 1) cancer vaccines and 2) adoptive medical care mistreatment Antigen-specific T cell transfer (TCR factor therapy).

CANCER VACCINES :

These ar accustomed stimulate each resistance and specific immune effectors responses to empower stronger tumor-specific responses. These forms of vaccines embrace a) Vaccination with growth cells built to precise immunostimulatory molecules [Jinushi M, et al., 2008], b) Vaccination with recombinant infective agent vectors encryption growth antigens [Arlen PM, et al., 2008], c) vaccination with Dendritic cells expressing growth antigens [Lotem M, et al., 2006] and d) naked polymer vaccines [Parmiani G, et al., 1997].

ADOPTIVE THERAPY USINGANTIGEN-SPECIFIC T LYMPHOCYTES TRANSFER (TCR GENE THERAPY):

This is a treatment that uses a cancer patient's own T lymphocytes with anti-tumor activity expanded in vitro and re-infused into the patient [Rosenberg SA, et al., 2008]. However, for several patients with cancers it's tough to get tumor-reactive T lymphocytes. A possible answer to the current problem is that the transduction of genes secret writing tumor-reactive lymph cell receptor (TCR) into patient peripheral blood lymphocytes (PBL) to convert them

into tumor-reactive T cells [Morgan R. A, et al., 2003]. To be used in cistron medical aid, the TCR genes ought to be incorporated into a retroviral expression system accustomed convert PBL ex vivo, before reinfusion. Experiments in an exceedingly mouse model showed that T cells transduced with a animal virus secret writing a TCR against a self- Expressed ingredient matter will persist and performance in vivo in transgenic mice [de Witte, M. A., et al., 2006]. Thus in The last years analysis has begun on the utilization of TCR cistron medical aid as a method to regulate and eradicate malignancies. Recent findings support the thought that with the utilization of this technology it is possible to airt T-cell matter specificity to supply cytotoxic and helper T cells, which are functionally competent in vivo and show promising antitumour effects in humans [Morgan RA, et al., 2006].

CONCLUSION :

Gene medical care against cancer may be a reality with a promising future. The hope for a miracle cure for cancer is felt within the ideas that sustain sequence medical care however not nevertheless in its reality. It is a therapeutic space that has much simply begun and this makes the primary industrial vectors expensive. Vectors square measure helpful in terribly specific cancers and patients and though they are doing not yet give a cure, they are doing improve patient quality of life and can still do thus a lot of and more. This sort of medical care appears to be AN adequate path to follow to with success fight malignant tumors. However, there's still an extended thanks to go before the perfect vector is found.

REFERENCE :

1. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006;4:218-227.
2. Edelstein ML, Abedi MR and Wixon Jo. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med. 2007; 9:833-842.
3. Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an Essential relationship. Cancer Chemother Pharmacol. 2009;63:571-582.
4. Rojas-Martínez A, Martínez-Dávila IA, Hernández-García A, Aguilar-Córdova E, Barrera-Saldaña HA. Genetic therapy of cancer. Rev Invest Clin. 2002;54(1):57-67
5. Nemerow GR. Biology of Adenovirus cell entry. In: Curiel DT and Douglas JT. Adenoviral vectors for gene therapy. USA. Academic Press. 2002.p 19-32.
6. Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors. Curr Opin Mol Ther. 2005;7:317-325.
7. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. Eradication of Solid Human Breast Tumors in Nude Mice with an intravenously Injected Light-Emitting Oncolytic Vaccinia Virus. Cancer Res. 2007; 67:10038-10046
8. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther. 2004;4:575-588.
9. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an Old dog. Mol Ther. 2005;11:180-195
10. Shen Y, Post L, Viral vector and their applications. In: Knipe DM, Howley PM, Diane E. Griffin. Fields virology. Edition 5. USA. Lippincott Williams & Wilkins 2007. P 540-558.
11. Nair V. Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther. 2008;10:431-438.
12. Park K, Kim WJ, Cho YH, Lee YI, Lee H, Jeong S, Cho ES, Chang SI, Moon SK, Kang BS, Kim YJ, Cho SH. Cancer gene therapy using adeno-associated virus vectors. Front Biosci. 2008 Jan 1;13:2653-2659.
13. Park K, Kim WJ, Cho YH, Lee YI, Lee H, Jeong S, Cho ES, Chang SI, Moon SK, Kang BS, Kim YJ, Cho SH. Cancer gene therapy using adeno-associated virus vectors.Front Biosci. 2008 Jan 1;13:2653-2659
14. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a Review. Oncol Res. 1997;9:313-325.
15. Belousova N, Mikheeva G, Gelovani J, Krasnykh V. Modification of adenovirus capsid With a designed protein ligand yields a gene vector targeted to a major molecular Marker of cancer. J Virol. 2008;82:630-637.
16. Parney IF and Chang LJ, Cancer immunogene therapy: a review. J. Biomed Sci. 2003;10:37-43
17. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after Transfer of genetically engineered lymphocytes. Science 2006;314:126-129.
18. Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E.WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis. 2008;40:113-116.
19. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008;222:287-298.
20. Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. Safety and immunologic response of A viral vaccine to prostate-specific antigen in combination with radiation therapy when Metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res. 2008;14:5284-5291.

21. Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR. Presentation of tumor antigens by dendritic cells genetically modified with viral and Nonviral vectors. J Immunother. 2006;29:616-627.
22. Schuurhuis DH, Lesterhuis WJ, Kramer M, Looman MG, van Hout-Kuijer M, Schreibelt G, Boullart AC, Aarntzen EH, Benitez-Ribas D, Figdor CG, Punt CJ, de Vries IJ, Adema GJ. Polyinosinic polycytidylic acid prevents efficient antigen Expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother. 2009; 58:1109-1115.
23. Parmiani G, Colombo MP, Melani C, Arienti F. Cytokine gene transduction in the Immunotherapy of cancer. Adv Pharmacol. 1997;40:259-307.
24. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
25. Morgan, R. A., M. E. Dudley, Y. Y. Yu, Z. Zheng, P. F. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. High efficiency Z] TCR Gene transfer into primary human lymphocytes affords avid recognition of melanoma Tumor antigen glycoprotein 100 and does not alter the recognition of autologous Melanoma antigens. J Immunol. 2003;171:3287–3295.
26. De Witte, M. A., M. Coccoris, M. C. Wolkers, M. D. van den Boom, E. M. Mesman, J. Y. Song, M. van der Valk, J. B. Haanen, and T. N. Schumacher. Targeting self antigens Through allogeneic TCR gene transfer. Blood. 2006;180:870–877.